Gilead CAR-T Cancer Therapy Capacity to Quadruple by 2026 Gilead CAR-T Cancer Therapy Capacity to Quadruple by 2026
Gilead Sciences will be able to quadruple production of its cell therapy cancer treatments by 2026 due to improvements in the U.S. biotech ' s manufacturing processes, an...Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 15, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Next-generation CAR and TCR Cancer Therapies
From smart receptors to novel biologics, scientists plan to overcome the challenges
of treating solid tumors. (Source: The Scientist)
Source: The Scientist - March 15, 2024 Category: Science Tags: Features Magazine Issue Source Type: news
QT Imaging to deliver Breast Acoustic CT scanner to research centers
QT Imaging Holdings is delivering its Breast Acoustic CT scanner in collaboration with research centers in the U.S. and Canada.
The company is collaborating with the Department of Radiation Oncology and Radiation Treatment Program at the Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, and the University of Illinois, Urbana-Champaign. This collaboration is part of a five-year research grant from National Institutes of Health/National Cancer Institute to develop an inexpensive, portable, safe, and repeatable imaging approach that can accurately identify early response of breast cancer patients to neoadjuvant ...
Source: AuntMinnie.com Headlines - March 14, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
New Immune-Focused Therapy, CAR T Cell Therapy, Shrinks Aggressive Brain Tumors
THURSDAY, March 14, 2024 -- Delivering dual-targeted, immune-focused CAR T cancer therapy via a patient ' s spinal fluid quickly shrank deadly brain tumors, researchers report.
CAR T therapy harnesses the power of the patient ' s immune system T-cells,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 14, 2024 Category: General Medicine Source Type: news
Drug Discount May Boost Adherence to Prostate Cancer Therapy Drug Discount May Boost Adherence to Prostate Cancer Therapy
The 340B drug discount program was not associated with oral specialty drug use in advanced prostate cancer but was linked to better adherence to medication in more vulnerable patients.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 11, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
'Silicon Forest' lab gets a piece of a $25M global children's cancer initiative grant
The Children ’s Cancer Therapy Development Institute is part of a five-member global consortium. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 6, 2024 Category: Biotechnology Authors: Elizabeth Hayes Source Type: news
Cancer is no longer a death sentence, but treatments still have a long way to go
Recently, the US Food and Drug Administration approved a first-of-its-kind cancer therapy to treat aggresive forms of skin cancer. It has us thinking of the long history of cancer. One of the first recorded mentions of cancer appears in an ancient Egyptian text from around 3000 B.C. And although we now know much more about how cancer begins — as a series of mutations in someone's DNA — it's a disease people are still grappling with how to cure cancers today. This episode, cancer epidemiologist Mariana Stern talks about cancer history and treatment today — plus, why some people are more prone to certain cancers and wh...
Source: NPR Health and Science - March 4, 2024 Category: Consumer Health News Authors: Berly McCoy Source Type: news
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., March 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 10,250 restricted stock units (RSUs) to two newly-hired employees.... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 1, 2024 Category: Pharmaceuticals Source Type: news
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., March 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on March 1, 2024 the Company granted inducement awards to purchase up to 42,800... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 1, 2024 Category: Pharmaceuticals Source Type: news
New cancer therapy approved by FDA supercharges body ’s immune system
After undergoing surgery, radiation and three different therapies, Scott Goedeke faced a tough reality: The cancer that first surfaced on the roof of his mouth had spread to a lymph node in his neck. So the 58-year-old health-care consultant agreed to an experimental treatment that would deploy…#scottgoedeke #sitemancancercenter #stlouis #fda #steverosenberg #iovance #frederickvogt #jasonbock #ctmc (Source: Reuters: Health)
Source: Reuters: Health - February 21, 2024 Category: Consumer Health News Source Type: news
Bi-weekly Dose Of Johnson & Johnson's Blood Cancer Therapy Gets US FDA Approval Bi-weekly Dose Of Johnson & Johnson's Blood Cancer Therapy Gets US FDA Approval
The U.S. Food and Drug Administration has approved a bi-weekly dose of Johnson& Johnson ' s blood cancer therapy Tecvayli, the drugmaker said on Tuesday.Reuters Health Information (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - February 20, 2024 Category: Internal Medicine Tags: Hematology-Oncology Source Type: news
GEHC, European Society of Radiology renew ECR collaboration
GE HealthCare (GEHC) and the European Society of Radiology have renewed their plan to collaborate during the upcoming European Congress of Radiology meeting to be held in Vienna, Austria.The meeting's theme is "Next Generation Radiology," and GEHC plans to highlight its commitment to tailored patient care with a focus on oncology, cardiology, and neurology, it said.On February 28, GE HealthCare International President and CEO Elie Chaillot and ESR President Prof. Carlo Catalano, MD, of La Sapienza University of Rome Hospital in Italy, will participate in a session that will outline GEHC's "care pathways" approach. The co...
Source: AuntMinnie.com Headlines - February 12, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News ECR Source Type: news
Commentary: The small-molecule 'penalty' is a threat to Mass. biotech sector
In Massachusetts, the convergence of brilliant minds and entrepreneurial spirit has given rise to transformative breakthroughs that are shaping the future of medicine: mRNA vaccines, targeted cancer therapies, gene-editing technology, and more. These advances are not an accident, but rather a product of an ecosystem of academic research institutions, venture funds, small biotech companies and large manufacturers.
This ecosystem is now adapting to new realities set in place by last year's Inflation… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 9, 2024 Category: Pharmaceuticals Authors: Kendalle Burlin O'Connell, John Stanford Source Type: news
US FDA Puts Hold on Gilead's Blood Cancer Therapy Trials US FDA Puts Hold on Gilead's Blood Cancer Therapy Trials
Gilead Sciences said on Wednesday the U.S. Food and Drug Administration had put a hold on trials testing the company ' s blood cancer drug following increased risk of patient...Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 7, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
LoRusso named the Amy and Joseph Perella Professor of Medicine
Patricia LoRusso is an internationally recognized expert in drug development and early-phase clinical investigation of novel cancer therapies. (Source: Yale Science and Health News)
Source: Yale Science and Health News - February 5, 2024 Category: Universities & Medical Training Source Type: news